These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 24885947)

  • 1. Both radical prostatectomy following treatment with neoadjuvant LHRH agonist and estramustine and radiotherapy following treatment with neoadjuvant hormonal therapy achieved favorable oncological outcome in high-risk prostate cancer: a propensity-score matching analysis.
    Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Aoki M; Takai Y
    World J Surg Oncol; 2014 Apr; 12():134. PubMed ID: 24885947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis.
    Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
    Int J Clin Oncol; 2015 Oct; 20(5):1018-25. PubMed ID: 25681879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of a neoadjuvant gonadotropin-releasing hormone antagonist plus low-dose estramustine phosphate in high-risk prostate cancer: a single-center study.
    Hagiwara K; Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Tobisawa Y; Yoneyama T
    Int Urol Nephrol; 2017 May; 49(5):811-816. PubMed ID: 28213801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and effectiveness of neoadjuvant luteinizing hormone-releasing hormone agonist plus low-dose estramustine phosphate in high-risk prostate cancer: a prospective single-arm study.
    Koie T; Ohyama C; Yamamoto H; Hatakeyama S; Yoneyama T; Hashimoto Y; Kamimura N
    Prostate Cancer Prostatic Dis; 2012 Dec; 15(4):397-401. PubMed ID: 22890389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncological outcome of neoadjuvant low-dose estramustine plus LHRH agonist/antagonist followed by extended radical prostatectomy for Japanese patients with high-risk localized prostate cancer: a prospective single-arm study.
    Enokida H; Yamada Y; Tatarano S; Yoshino H; Yonemori M; Sakaguchi T; Nishimura H; Eura R; Nakagawa M
    Jpn J Clin Oncol; 2020 Jan; 50(1):66-72. PubMed ID: 31665352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
    Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
    Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall survival of high-risk prostate cancer patients who received neoadjuvant chemohormonal therapy followed by radical prostatectomy at a single institution.
    Fujita N; Koie T; Ohyama C; Tanaka Y; Soma O; Matsumoto T; Yamamoto H; Imai A; Tobisawa Y; Yoneyama T; Hatakeyama S; Hashimoto Y
    Int J Clin Oncol; 2017 Dec; 22(6):1087-1093. PubMed ID: 28681153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radical Prostatectomy With and Without Neoadjuvant Chemohormonal Pretreatment for High-Risk Localized Prostate Cancer: A Comparative Propensity Score Matched Analysis.
    Narita S; Nara T; Kanda S; Numakura K; Saito M; Inoue T; Satoh S; Nanjo H; Tsuchiya N; Mitsuzuka K; Koie T; Kawamura S; Ohyama C; Tochigi T; Arai Y; Habuchi T
    Clin Genitourin Cancer; 2019 Feb; 17(1):e113-e122. PubMed ID: 30391137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of extended lymph node dissection versus neoadjuvant therapy with limited lymph node dissection on biochemical recurrence in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis.
    Narita T; Koie T; Ookubo T; Mitsuzuka K; Narita S; Yamamoto H; Inoue T; Hatakeyama S; Kawamura S; Tochigi T; Habuchi T; Arai Y; Ohyama C
    Med Oncol; 2017 Jan; 34(1):1. PubMed ID: 27889880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
    Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
    Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.
    Boehm K; Schiffmann J; Tian Z; Lesmana H; Larcher A; Mandel P; Karakiewicz PI; Graefen M; Schwarz R; Krüll A; Tilki D
    Urol Oncol; 2016 Mar; 34(3):119.e11-8. PubMed ID: 26602027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
    D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Blank K; Broderick GA; Tomaszewski JE; Renshaw AA; Kaplan I; Beard CJ; Wein A
    JAMA; 1998 Sep; 280(11):969-74. PubMed ID: 9749478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant LHRH analog plus estramustine phosphate combined with three-dimensional conformal radiotherapy for intermediate- to high-risk prostate cancer: a randomized study.
    Hirano D; Nagane Y; Satoh K; Mochida J; Sugimoto S; Ichinose T; Takahashi S; Maebayashi T; Saitoh T
    Int Urol Nephrol; 2010 Mar; 42(1):81-8. PubMed ID: 19449118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer.
    Narita S; Tsuchiya N; Kumazawa T; Maita S; Numakura K; Obara T; Tsuruta H; Saito M; Inoue T; Horikawa Y; Satoh S; Nanjyo H; Habuchi T
    World J Surg Oncol; 2012 Jan; 10():1. PubMed ID: 22214417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer.
    Tosco L; Laenen A; Briganti A; Gontero P; Karnes RJ; Albersen M; Bastian PJ; Chlosta P; Claessens F; Chun FK; Everaerts W; Gratzke C; Graefen M; Kneitz B; Marchioro G; Salas RS; Tombal B; Van den Broeck T; Moris L; Battaglia A; van der Poel H; Walz J; Bossi A; De Meerleer G; Haustermans K; Van Poppel H; Spahn M; Joniau S
    Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):407-412. PubMed ID: 28485390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness comparison between neoadjuvant chemohormonal therapy and extended pelvic lymph node dissection in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis.
    Matsumoto T; Hatakeyama S; Ookubo T; Mitsuzuka K; Narita S; Inoue T; Yamashita S; Narita T; Koie T; Kawamura S; Tochigi T; Tsuchiya N; Habuchi T; Arai Y; Ohyama C
    Med Oncol; 2017 Oct; 34(12):190. PubMed ID: 29090390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy.
    Cortés-González JR; Castellanos E; Sandberg K; Eriksson MH; Wiklund P; Carlsson S; Cohn-Cedermark G; Harmenberg U; Gustafsson O; Levitt SH; Lennernäs B; Brandberg Y; Márquez M; Kälkner KM; Nilsson S
    Int J Oncol; 2013 Jan; 42(1):109-17. PubMed ID: 23151842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy.
    Adam M; Tennstedt P; Lanwehr D; Tilki D; Steuber T; Beyer B; Thederan I; Heinzer H; Haese A; Salomon G; Budäus L; Michl U; Pehrke D; Stattin P; Bernard J; Klaus B; Pompe RS; Petersen C; Huland H; Graefen M; Schwarz R; Huber W; Loeb S; Schlomm T
    Eur Urol; 2017 Mar; 71(3):330-336. PubMed ID: 27887941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
    Noguchi M; Noda S; Yoshida M; Ueda S; Shiraishi T; Itoh K;
    Int J Urol; 2004 Feb; 11(2):103-9. PubMed ID: 14706014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
    Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
    Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.